Amneal announces patent litigation settlement agreement with Actavis concerning Rytary®
Amneal Pharmaceuticals announced it has entered into a settlement agreement with Actavis Laboratories resolving patent litigation related to Rytary® (carbidopa-levodopa). The litigation resulted from Actavis's submission of an ANDA to the FDA seeking approval to market a generic version of Rytary. June 20, 2018